A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2016

At a glance

  • Drugs SM 04554 (Primary)
  • Indications Alopecia; Male pattern baldness
  • Focus Therapeutic Use
  • Sponsors Samumed
  • Most Recent Events

    • 07 Mar 2016 Results presented at the 74th Annual Meeting Of The American Academy Of Dermatology (AAD), according to a Samumed media release.
    • 04 Dec 2015 Results published in Samumed media release.
    • 04 Dec 2015 Primary endpoint has been met (Change in non-vellus hair count), as per Samumed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top